Packaging systems for human recombinant adenovirus to be used in gene therapy Number:7,052,881 from the United States Patent and Trademark Office (PTO) owispatent Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large-scale production of recombinant adenoviruses. A system for use with the invention produces replication-defective adenovirus. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, has at least one functional encapsidation signal and at least one functional Inverted Terminal Repeat, and lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.<H recombinant, adenovirus, Packaging, syste, 7052881.html, Patent, pto, 7052881

Title: Packaging systems for human recombinant adenovirus to be used in gene therapy

Abstract: Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large-scale production of recombinant adenoviruses. A system for use with the invention produces replication-defective adenovirus. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, has at least one functional encapsidation signal and at least one functional Inverted Terminal Repeat, and lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.

Patent Number: 7,052,881 Issued on 05/30/2006 to Fallaux, et al.

Inventors: Fallaux; Frits J. (Leiderdorp, NL); Hoeben; Robert C. (Leiden, NL); van der Eb; Alex Jan (Oegstgeest, NL); Bout; Abraham (Moerkapelle, NL); Valerio; Domenico (Oegstgeest, NL)
Assignee: Crucell Holland B.V. (Leiden, NL)

Appl. No.: 850140

Filed: May 20, 2004

Related U.S. Patent Documents


Application Number	Filing Date	Patent Number	Issue Date
09918029	Jul., 2001	6783980
09506548	Feb., 2000	6602706
09334765	Jun., 1999	6238893
08793170	Mar., 1997
PCT/NL96/00244	Jun., 1996

Foreign Application Priority Data


Jun 15, 1995 [EP]			95201611
Jun 26, 1995 [EP]			95201728

Current U.S. Class: 435/91.4 ; 435/320.1; 435/325; 435/455; 435/456; 435/457

Current International Class: C12N 15/64 (20060101); C12N 15/861 (20060101); C12N 5/08 (20060101)

Field of Search: 424/93.2 435/6,91.2

References Cited [Referenced By]

U.S. Patent Documents


4405712	September 1983	Vande Woude et al.
4487829	December 1984	Sharp et al.
4497796	February 1985	Salser et al.
4517686	May 1985	Ruoslahti et al.
4578079	March 1986	Ruoslahti et al.
4589881	May 1986	Pierschbacher et al.
4593002	June 1986	Dulbecco
4727028	February 1988	Santerre et al.
4740463	April 1988	Weinberg et al.
4792525	December 1988	Ruoslahti et al.
4797368	January 1989	Carter et al.
4956281	September 1990	Wallner et al.
5024939	June 1991	Gorman
5096815	March 1992	Ladner et al.
5166320	November 1992	Wu et al.
5190931	March 1993	Inouye
5198346	March 1993	Ladner et al.
5204445	April 1993	Plow et al.
5208149	May 1993	Inouye
5223394	June 1993	Wallner
5223409	June 1993	Ladner et al.
5240846	August 1993	Collins et al.
5246921	September 1993	Reddy et al.
5332567	July 1994	Goldenberg
5349053	September 1994	Landolfi
5378618	January 1995	Sternberg et al.
5403484	April 1995	Ladner et al.
5436146	July 1995	Shenk et al.
5443953	August 1995	Hansen et al.
5474935	December 1995	Chatterjee et al.
5518913	May 1996	Massie et al.
5521291	May 1996	Curiel et al.
5534423	July 1996	Plasson et al.
5543328	August 1996	Mcclelland et al.
5545522	August 1996	Van Gelder et al.
5547932	August 1996	Curiel et al.
5552311	September 1996	Sorscher et al.
5559099	September 1996	Wickham et al.
5571698	November 1996	Ladner et al.
5622699	April 1997	Ruoslahti et al.
5652224	July 1997	Wilson et al.
5707618	January 1998	Armentano et al.
5712136	January 1998	Wickham et al.
5731190	March 1998	Wickham et al.
5753500	May 1998	Shenk et al.
5756086	May 1998	Mcclelland et al.
5770442	June 1998	Wickham et al.
5824544	October 1998	Armentano et al.
5837511	November 1998	Falck-Pedersen et al.
5846782	December 1998	Wickham et al.
5849561	December 1998	Falck-Pedersen
5851806	December 1998	Kovesdi et al.
5856152	January 1999	Wilson et al.
5871727	February 1999	Curiel
5871982	February 1999	Wilson et al.
5877011	March 1999	Armentano et al.
5891690	April 1999	Massie
5919676	July 1999	Graham et al.
5922315	July 1999	Roy
5994106	November 1999	Kovesdi et al.
5994128	November 1999	Fallaux et al.
6033908	March 2000	Bout et al.
6040174	March 2000	Imler et al.
6051430	April 2000	Plasterk et al.
6057155	May 2000	Wickham et al.
6100086	August 2000	Kaplan et al.
6127525	October 2000	Crystal et al.
6140103	October 2000	Einerhand et al.
6203975	March 2001	Wilson
6204052	March 2001	Bout et al.
6210939	April 2001	Gregory et al.
6232105	May 2001	Einerhand et al.
6238893	May 2001	Hoeben et al.
6265212	July 2001	Fallaux et al.
6287857	September 2001	O'riordan et al.
6306652	October 2001	Fallaux et al.
6486133	November 2002	Herlyn et al.
6492169	December 2002	Vogels et al.
6602706	August 2003	Fallaux et al.
6669942	December 2003	Perricaudet et al.
6783980	August 2004	Fallaux et al.
2002/0102732	August 2002	Fallaux et al.
2002/0151032	October 2002	Fallaux et al.
2002/0164802	November 2002	Fallaux et al.
2002/0173039	November 2002	Fallaux et al.
2003/0104626	June 2003	Fallaux et al.
2004/0087027	May 2004	Gregory et al.

Foreign Patent Documents


A-28533/95	Mar., 1996	AU
2053187	Apr., 1993	CA
2117668	Sep., 1995	CA
117060	Aug., 1984	EP
259212	Aug., 1987	EP
95201611.1	Jun., 1995	EP
95201728.3	Jun., 1995	EP
1016726	Dec., 1998	EP
1067188	Jul., 1999	EP
1020529	Nov., 1999	EP
2 707 664	Jan., 1995	FR
WO 91/00360	Jan., 1991	WO
WO 91/05805	May., 1991	WO
WO 91/05871	May., 1991	WO
WO 92/02553	Feb., 1992	WO
WO 92/13081	Aug., 1992	WO
WO 93/03769	Mar., 1993	WO
WO 93/06223	Apr., 1993	WO
WO 93/07282	Apr., 1993	WO
WO 93/07283	Apr., 1993	WO
WO 94/08026	Apr., 1994	WO
WO 94/10323	May., 1994	WO
WO 94/11506	May., 1994	WO
WO 94/12649	Jun., 1994	WO
WO 94/15644	Jul., 1994	WO
WO 94/17832	Aug., 1994	WO
WO 94/23582	Oct., 1994	WO
WO 94/24297	Oct., 1994	WO
WO 94/24299	Oct., 1994	WO
WO 94/26914	Nov., 1994	WO
WO 94/26915	Nov., 1994	WO
WO 94/28152	Dec., 1994	WO
WO 94/28938	Dec., 1994	WO
WO 95/00655	Jan., 1995	WO
WO 95/02697	Jan., 1995	WO
WO 95/05201	Feb., 1995	WO
WO 95/06745	Mar., 1995	WO
WO 95/14785	Jun., 1995	WO
WO 95/16037	Jun., 1995	WO
WO 95/16772	Jun., 1995	WO
WO 95/21259	Aug., 1995	WO
WO 95/26411	Oct., 1995	WO
WO 95/26412	Oct., 1995	WO
WO 95/27071	Oct., 1995	WO
WO 95/31187	Nov., 1995	WO
WO 95/31566	Nov., 1995	WO
WO 95/34671	Dec., 1995	WO
WO 96/00326	Jan., 1996	WO
WO 96/00790	Jan., 1996	WO
WO 96/07739	Mar., 1996	WO
WO 96/10087	Apr., 1996	WO
WO 96/12030	Apr., 1996	WO
WO 96/13596	May., 1996	WO
WO 96/13597	May., 1996	WO
WO 96/13598	May., 1996	WO
WO 96/14061	May., 1996	WO
WO 96/14837	May., 1996	WO
WO 96/16676	Jun., 1996	WO
WO 96/17073	Jun., 1996	WO
WO 96/18418	Jun., 1996	WO
WO 96/18740	Jun., 1996	WO
WO 96/24453	Aug., 1996	WO
WO 96/26281	Aug., 1996	WO
WO 96/33280	Oct., 1996	WO
WO 96/35798	Nov., 1996	WO
WO 96/40955	Dec., 1996	WO
WO 97/00326	Jan., 1997	WO
WO 97/00947	Jan., 1997	WO
WO 97/04119	Feb., 1997	WO
WO 97/05255	Feb., 1997	WO
WO 97/12986	Apr., 1997	WO
WO 97/20575	Jun., 1997	WO
WO 97/38723	Oct., 1997	WO
WO 98/07865	Feb., 1998	WO
WO 98/11221	Mar., 1998	WO
WO 98/13499	Apr., 1998	WO
WO 98/22609	May., 1998	WO
WO 98/32842	Jul., 1998	WO
WO 98/40509	Sep., 1998	WO
WO 98/49300	Nov., 1998	WO
WO 98/50053	Nov., 1998	WO
WO 99/32647	Jul., 1999	WO
WO 99/47180	Sep., 1999	WO
WO 99/55132	Nov., 1999	WO
WO 99/58646	Nov., 1999	WO
WO 00/03029	Jan., 2000	WO
WO 00/24730	May., 2000	WO
WO 00/31285	Jun., 2000	WO
WO 00/52186	Sep., 2000	WO
WO 00/70071	Nov., 2000	WO
WO 01/04334	Jan., 2001	WO
WO 01/44280	Jun., 2001	WO
WO 01/90158	Nov., 2001	WO
WO 02/24730	Mar., 2002	WO
WO 02/27006	Apr., 2002	WO

Other References

Abrahamsen et al., "Construction of an Adenovirus Type 7a E1A Vector," Journal of Virology, Nov. 1997, p. 8946-8951 vol. 71, No. 11. cited by other .
Albiges-Rizo et al., "Human Adenovirus Serotype 3 Fiber Protein," Journal of Biological Chemistry, 266(6), 3961-3967 (1991). cited by other .
Anderson, Nature, "Human gene therapy," Apr. 1998, vol. 392, pp. 25-30. cited by other .
Athappilly et al., "The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2.cndot.9 A Resolution," J. Mol. Biol. (1994) 242, 430-455. cited by other .
Bai et al., "Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells," Journal of Virology, 67(9), 5198-5205 (1993). cited by other .
Bailey et al., "Phylogenetic Relationships among Adenovirus Serotypes," Virology, 205, 439-452 (1994). cited by other .
Ball-Goodrich et al., "Parvoviral Target Cell Specificity: Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid," Virology, 184, 175-186 (1991). cited by other .
Basler et al., Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, 1996, Gene 170:249-254. cited by other .
Basler et al., "Subgroup B Adenovirus Type 35 Early Region 3 mRNAs Differ from Those of the Subgroup C Adenoviruses," Virology 215, 165-177 (1996). cited by other .
Batra et al., "Receptor-mediated gene delivery employing lectin-binding specificity," Gene Therapy, 1, 255-260 (1994). cited by other .
Berendsen, Herman J.C., A Glimpse of the Holy Grail, Science, 1998, vol. 282, pp. 642-643. cited by other .
Boursnell et al., "In vitro construction of a recombinant adenovirus Ad2:Ad5," Gene, 13, 311-317 (1981). cited by other .
Bridge et al., "Adenovirus Early Region 4 and Viral DNA Synthesis," Virology 193, 794-801 (1993). cited by other .
Brody et al., "Adenovirus-Mediated in Vivo Gene Transfer," Annals New York Academy of Sciences pp. 90-100. cited by other .
Caillet-Boudin et al., "Functional and Structural Effects of an Ala to Val Mutation in the Adenovirus Serotype 2 Fibre," J. Mol. Biol., 217, 477-486 (1991). cited by other .
Chiu et al., Folding & Design, "Optimizing energy potentials for success in protein tertiary structure prediction," May 1998, 3:223-228. cited by other .
Chroboczek et al., Adenovirus Fiber, Current Topics in Microbiology and Immunology 1995;199 (Pt 1) pp. 163-200. cited by other .
Chu et al., "Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins," Gene Therapy, 1, 292-299 (1994). cite- d by other .
Cotten et al., "Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels," Proc. Natl. Acad. Sci. USA, 87, 4033-4037 (1990). cited by other .
Cotten et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992). cited by other .
Crawford-Miksza et al., "Adenovirus Serotype Evolution Is Driven by Illegitimate Recombination in the Hypervariable Regions of the Hexon Protein," Virology, 224, 357-367 (1996). cited by other .
Crawford-Miksza et al., "Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues," Journal of Virology, Mar. 1996, p. 1836-1844. cited by other .
Crompton et al., "Expression of a foreign epitope on the surface of the adenovirus hexon," J. Gen. Virol., 75(1), 133-139 (1994). cited by other .
Crystal, Ronald G., "Transfer of Genes to Humans: Lessons and Obstacles to Success," Science, 270, 404-410 (1995). cited by other .
Curiel et al., "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," Human Gene Theraphy, 3, 147-154 (1992). cited by other .
Curiel et al., "Adenovirus enhancement of transferring-polylysine-mediated gene delivery," Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991). cited by other .
De Jong et al., "Adenovirus Isolates From Urine of Patients with Acquired Immunodeficiency Syndrome," The Lancet, Jun. 11, 1983 pp. 1293-1296. cite- d by other .
De Jong et al., Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively, Journal of Clinical Microbiology, Dec. 1999, p. 3940-45, vol. 37, No. 12, American Society for Microbiology. cited by other .
Defer et al., "Human Adenovirus-Host Cell Interactions: Comparative Study with Members of Subgroups B and C," Journal of Virology, 64(8), 3661-3673 (1990). cited by other .
Deonarain, "Ligand-targeted receptor-mediated vectors for gene delivery," (1998) Expert Opin. Ther. Pat. 8: 53-69. cited by other .
Dukema et al., "Transformation of Primary Rat Kidney Cells by DNA Fragments of Weakly Oncogenic Adenoviruses," Journal of Virology, Dec. 1979, p. 943-950. cited by other .
Douglas J T et al.: "Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors" Neuromusclar Disorders, Pergamon Press, GB, vol. 7, Jul. 1997, pp. 284-298, XP002079944 ISSN: 0960-8966. cited by other .
Dupuit et al., "Regenerating Cells in Human Airway Surface Epithelium Represent Preferential Targets for Recombinant Adenovirus," Human Gene Therapy, 6, 1185-1193 (1995). cited by other .
Eck et al., "Gene-Based Therapy," (1996) Goodman & Gillman's The Pharmacological Basis of Therapeutics, Mc-Graw-Hill, New York, N.Y., pp. 77-101. cited by other .
Etienne-Julan et al., "The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker," Journal of General Virology, 73, 3251-3255 (1992). cited by other .
Falgout et al., "Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene," Journal of Virology, 62(2), 622-625 (1988). cited by other .
Flomenberg et al., "Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts," The Journal Of Infectious Diseases vol. 155, No. 6, Jun. 1987. cited by other .
Francki et al., "Classification and Nomenclature of Viruses," Fifth Report of the International Committee on Taxonomy of Viruses; Virology Division of the International Union of Microbiology Societies pp. 140-143. cited by other .
Gall et al., "Construction and characterization of Hexon-Chimeric Adenoviruses: Specification of adenovirus serotype," 72(12) Journal of Virology 10260-64 (1998). cited by other .
Gall et al., "Adenovirus Type 5 and 7 Capsid Chimera: Fiber Replacement Alters Receptor Tropism without Affecting Primary Immune Neutralization Epitopes," Journal Of Virology, Apr. 1996, p. 2116-2123. cited by other .
George et al., "Gene therapy progress and prospects: adenoviral vectors," Gene Therapy (2003) 10, 1135-1141. cited by other .
Gorecki, "Prospects and problems of gene therapy: an update," (2001) Expert Opin. Emerging Drugs 6(2): 187-98. cited by other .
Greber et al., "Stepwise Dismantling of Adenovirus 2 during Entry into Cells," Cell, 75, 477-486 (1993). cited by other .
Green et al., "Evidence for a repeating cross- sheet structure in the adenovirus fibre," EMBO Journal, 2(8), 1357-1365 (1983). cited by other .
Grubb et al., Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans, Nature, 371, 802-806 (1994). cited by other .
Gurunathan et al., American Association of Immunologists, "CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Indicates Protective Immunity to Infectious and Tumor Challenge," 1998, 161:4563-4571. cited by other .
Han et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci. USA, 92, 9747-9751 (1995). cited by other .
He et al., "A simplified system for generating recombinant adenoviruses," Proc. Natl. Acad. Sci. USA vol. 95, pp. 2509-2514, Mar. 1998. cited by other .
Henry et al., "Characterization of the Knob Domain of the Adenovirus Type 5 Fiber Protein Expressed in Escherichia coli," Journal of Virology, 68(8), 5239-5246 (1994). cited by other .
Hidaka, Chisa, et al., "CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts," 103(4) The Journal of Clinical Investigation 579-87 (Feb. 1999). cited by other .
Hierholzer et al., "Adenoviruses from Patients with AIDS: A Plethora of Serotypes and A Description of Five New Serotypes of Subgenus D (Types 43-47)," The Journal Of Infectious Diseases vol. 158, No. 4 Oct. 1988. cited by other .
Hong et al., "The Amino Terminus of the Adenovirus Fiber Protein Encodes the Nuclear Localization Signal," Virology, 185(2), 758-767 (1991). cited by other .
Horvath et al., "Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection," Journal of Virology, 62(1), 341-345 (1988). cited by other .
Huang et al., "Upregulation of Integrins .sub.y3 and .sub.y5 on Human Monocytes and T Lymphocytes Facilitates Adenovirus-Mediated Gene Delivery," Journal of Virology, 69(4), 2257-2263 (1995). cited by other .
Jolly; viral vector systems for gene therapy, 1994, Cancer Gene Therapy, vol. 1, No. 1: 51-64. cited by other .
Kang et al., "Molecular Cloning And Physical Mapping Of The Dna Of Human Adenovirus Type 35," Acta Microbiologica Hungarica 36 (1), 67-75 (1989). cited by other .
Kang et al., "Relationship Of EI And E3 Regions Of Human Adenovirus 35 To Those Of Human Adenovirus Subgroups A, C And D," Acta Microbiologica Hungarica 36 (4), pp. 445-457 (1989). cited by other .
Karayan et al., "Oligomerization of Recombinant Penton Base of Adenovirus Type 2 and Its Assembly with Fiber in Baculovirus-Infected Cells," Virology, 202, 782-795 (1994). cited by other .
Kass-Eisler et al., "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo," Proc. Natl. Acad. Sci. USA, 90, 11498-11502 (1993). cited by other .
Kmiec, "Gene Therapy," American Scientist, vol. 87, pp. 240. cited by othe- r .
Komoriya et al., The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CSI) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine,: Journal of Biological Chemistry, 266(23), 15075-15079 (1991). cited by other .
Krasnykh et al.: "Generation Of Recombinant Adenovirus Vectors With Modified Fibers For Altering Viral Tropism" Journal Of Virology, The American Society For Microbiology, US, vol. 70, No. 10, Oct. 1, 1996, pp. 6839-6846, XP002067518 ISSN: 0022-538X. cited by other .
Lattanzi, Laura, et al., "High Efficiency Myogenic Conversion of Human Fibroblasts by Adenoviral Vector-mediated MyoD Gene Transfer," 101(10) J. Clin. Invest. 2119-28 (May 1998). cited by other .
Lee et al., "The constitutive expression of the immunomodulatory gp 19k protein in E1', E3' adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector," Gene Therapy (1995) 2, 256-262. cited by other .
Levrero et al., "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo," Gene, 101 (1991) 195-202. cited by other .
Li et al., "Genetic Relationship between Thirteen Genome Types of Adenovirus 11, 34, and 35 with Different Tropisms," Intervirology 1991;32:338-350. cited by other .
Liu et al., Molecular Basis of the inflammatory response to adenovirus vectors. Gene Therapy (2003 10, 935-40. cited by other .
Maraveyas et al., "Targeted Immunotherapy B An update with special emphasis on ovarian cancer," Acta Oncologica, 32(7/8), 741-746 (1993). cited by other .
Mastrangeli et al., "Sero-Switch" Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype, Human Gene Therapy, 7, 79-87 (1996). cited by other .
Mathias et al., "Multiple Adenovirus Serotypes Use .nu. Integrins for Infection," Journal of Virology, 68(10), 6811-6814 (1994). cited by other .
Mautner et al., "Recombination in Adenovirus: DNA Sequence Analysis of Crossover Sites in Intertypic Recombinants," Virology, 131, 1-10 (1983). cited by other .
Mautner et al., "Recombination in Adenovirus: Analysis of Crossover Sites in Intertypic Overlap Recombinants," Virology, 139, 43-52, (1984). cited by other .
Merriam-Webster Dictionary (on line) retrieved from the internet<URL:htpp://www.m-w.com/cgi-bin/dictionary, "derive," 2002. cited by other .
Michael et al., "Addition of a short peptide ligand to the adenovirus fiber protien," Gene Therapy, 2, 660-668 (1995). cited by other .
Michael et al., "Binding-incompetent Adenovirus Facilitates Molecular Conjugate-mediated Gene Transfer by the Receptor-mediated Endocytosis Pathway," Journal of Biological Chemistry, 268(10), 6866-6869 (1993). cit- ed by other .
Miller et al., "Targeted vectors for gene therapy," FASEB Journal, 9, 190-199 (1995). cited by other .
Neda et al., "Chemical Modification of an Ecotropic Murine Leukemia Virus Results in Redirection of Its Target Cell Specificity," Journal of Biological Chemistry, 266(22), 14143-14146 (1991). cited by other .
Nemerow et al., "The Role of .alpha..nu. Integrins in Adenovirus Infection," Biology of Vitronectins and their Receptors, 177-184 (1993). cited by other .
Nemerow et al., "Adenovirus entry into host cells: a role for .alpha. integrins," Trends In Cell Biology, 4, 52-55 (1994). cited by other .
Novelli et al., "Deletion Analysis of Functional Domains in Baculovirus-Expressed Adenovirus Type 2 Fiber," Virology, 185, 365-376 (1991). cited by other .
Peteranderl et al., "Trimerization of the Heat Shock Transcription Factor by a Triple-Stranded -Helical Coiled-Coil," Biochemistry, 31, 12272-12276 (1992). cited by other .
Prince, "Gene Transfer: A Review Of Methods And Applications," Pathology (1998), 30, pp. 335-347. cited by other .
Pring-Akerblom et al., "Sequence Characterization and Comparison of Human Adenovirus Subgenus B and E Hexons," Virology, 212, 232-36 (1995). cited by other .
Ragot et al.,: "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice" Nature, Macmillan Journals Ltd. London, GB, vol. 361, No. 6413, 1993, pp. 647-650, XP002162515 ISSN: 0028-0836. cited by other .
Rea et al., "Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells," Journal Of Immunology, (Apr. 15, 2000) 166 (8) 5236-44.,--Apr. 15, 2001 XP002192775. cited by other .
Robbins et al., "Viral Vectors for Gene Therapy," Pharmacol. Ther. vol. 80, No. 1, pp. 35-47, 1998. cited by other .
Roberts et al., "Three-Dimensional Structure of the Adenovirus Major Coat Protein Hexon," Science, 232, 1148-51 (1986). cited by other .
Roelvink et al., The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F, Journal Of Virology, Oct. 1998, p. 7909-7915, vol. 72, No. 10. cited by other .
Romano, "Gene Transfer in Experimental Medicine," Drug & News Perspectives, vol. 16, No. 5, 2003, 13 pages. cited by other .
Russell et al., "Retroviral vectors displaying functional antibody fragments," Nucleic Acids Research, 21(5), 1081-1085 (1993). cited by oth- er .
Russell, "Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects," European Journal of Cancer, vol. 30A, No. 8, pp. 1165. cited by other .
Sabourin et al., "The molecular regulation of myogenesis," (2000) Clin. Genet. 57(1): 16-25. cited by other .
Schnurr et al., "Two New Candidate Adenovirus Serotypes," Intervirology 1993;36:79-83. cited by other .
Schulick et al., "Established Immunity Precludes Adenovirus-mediated Gene Transfer in Rat Carotid Arteries," The Journal of Clinical Investigation vol. 99, No. 2, Jan. 1997, 209-219. cited by other .
Segerman et al.: "Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines" Journal of Virology, The American Society for Microbiology, US, vol. 74, No. 3, Feb. 2000, pp. 1457-1467, XP002161682 ISSN: 0022-538X. cited by other .
Shayakhmetov et al., "Efficient Gene Transfer into Human CD34.sub.+Cells by a Retargeted Adenovirus Vector," Journal Of Virology, Mar. 2000, p. 2567-2583. cited by other .
Signas et al., "Adenovirus 3 Fiber Polypeptide Gene: Implications for the Structure of the Fiber Protein," Journal of Virology, 53(2), 672-678 (1985). cited by other .
Silver et al., "Interaction of Human Adenovirus Serotype 2 with Human Lymphoid Cells," Virology, 165, 377-387 (1988). cited by other .
Stevenson et al.; Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein, 1997, Journal of Virology, vol. 71: 4782-4790. cited by other .
Stewart et al., "Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy," EMBO Journal, 12(7), 2589-2599 (1993). cited by other .
Stratford-Perricaudet LD et al.: "Widespread Long-Term Gene Transfer To Mouse Skeletal Muscles And Heart" Journal Of Clinical Investigation, New York, NY, US, vol. 90 No. 2, Aug. 1992, ISSN: 0021-9738. cited by other .
Toogood et al., "The Adenovirus Type 40 Hexon: Sequence, Predicated Structure and Relationship to Other Adenovirus Hexons," J. gen. Virol (1989), 70, 3203-3214. cited by other .
Valderrama-Leon et al., "Restriction Endonuclease Mapping of Adenovirus 35, a Type Isolated from Immunocompromised Hosts," Journal Of Virology, Nov. 1985, p. 647-650. cited by other .
Verma et al., Nature, "Gene therapy-promises, problems and prospects," Sep. 1997, vol. 389, pp. 239-242. cited by other .
Wadell, "Molecular Epidemiology of Human Adenoviruses," Microbiology and Immunology, vol. 110 pp. 191-220. cited by other .
Wagner et al., "Coupling of adenovirus to transferring-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," Proc. Natl. Acad. Sci. USA, 89, 6099-6103 (1992). cited by other .
Watson et al., "An Antigenic Analysis of the Adenovirus Type 2 Fibre Polypeptide," Journal of Virology, 69, 525-535 (1988). cited by other .
Wickham et al., "Integrins .sub.y3 and .sub.y5 Promote Adenovirus Internalization but Not Virus Attachment," Cell, 73, 309-319 (1993). cite- d by other .
Wickham et al., "Integrin .sub.y5 Selectively Promotes Adenovirus Mediated Cell Membrane Permeabilization," Journal of Cell Biology, 127(1), 257-264 (1994). cited by other .
Wickham et al.: "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins," Journal of Virology, Nov. 1997, p. 8221-8229. cited by other .
Zhong et al.: "Recombinant Advenovirus Is An Efficient And Non-Pertubing Genetic Vector For Human Dendritic Cells" European Journal Of Immunology, Weinheim, DE, vol. 29, No. 3, 1999, pp. 964-972, XP000938797 ISSN: 0014-2980. cited by other .
Amalfitano et al., "Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors", Proc. Natl. Acad. Sci. USA, 93:3352-3356, Apr. 1996. cited by other .
Amalfitano et al., "Isolation and characterization of packaging cell lines that coexpress the adenovirus El, DNA polymerase, and preterminal proteins: implications for gene therapy", Gene Therapy, 4:258-263, 1997. cited by other .
Armentano et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion", Human Gene Therapy, 6:1343-1353, Oct. 1995. cited by other .
Bernards, Rene, et al., "Characterization of Cells Transformed by Ad5/Ad12 Hybrid Early Region 1 Plasmids", Virology , 120:422-432, 1982. cited by other .
Bernards, Rene, et al., "Role of Adenovirus Types 5 and 12 Early Region 1b Tumor Antigens in Oncogenic Transformation", Virology, 127:45-53, 1983. cited by other .
Brough et al., "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4", Journal of Virology, 70(9):6497-6501, Sep. 1996. cited by other .
Brough et al., "Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein", Virology, 190:624-634, 1992. cited by other .
Brough et al., "Multiple Functions of the Adenovirus DNA-Binding Protein Are Required for Efficient Viral DNA Synthesis", Virology, 196:269-281, 1993. cited by other .
Brough et al., "Restricted changes in the adenovirus DNA-binding protein that lead to extended host range or temperature sensitive phenotypes", Journal of Virology, vol. 55, pp. 206-212. cited by other .
Brough et al., Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4; Abstract Book CSH Conference On Gene Therapy, 42, 1996. cited by other .
Caravokyri et al., "Constitutive Episomal Expression o

Free Web Sudoku Puzzles.
Solve with your browser.

8 1 9
4 1 3
5 2
2 9 5 4
7 2
1 2 8 7
7 4
4 5 9
1 7 8

What is it?